Last updated: July 16, 2026
Endo v. Perrigo UK FINCO Limited Partnership (1:19-cv-00437-MN): Litigation Summary, Patent Claims, and Exclusivity/Generic Risk
Executive summary: The case Endo Pharmaceuticals Inc. v. Perrigo UK FINCO Limited Partnership, 1:19-cv-00437-MN, is a US Hatch-Waxman-style patent infringement dispute tied to Perrigo’s generic plans for an Endo-branded product. The docket reflects early-stage litigation activity in 2019 with subsequent procedural developments. This write-up provides a structured litigation summary and business-risk analysis focused on (1) claim coverage and typical carve-outs, (2) generic entry timing and Paragraph IV exposure mechanics, and (3) likely settlement posture and downstream regulatory impact, using the case-level identifiers provided.
Scope note on boundaries: A full, case-accurate litigation analysis requires docket-level fields (complaint counts, asserted patents, ANDA number, claim charts, infringement grounds, and any final judgment/settlement terms). With only the case caption and docket number available in the prompt, a complete and accurate patent-and-claim mapping cannot be produced without introducing external, non-provided facts.
What is the Endo Pharmaceuticals v. Perrigo UK FINCO Limited Partnership lawsuit about (1:19-cv-00437-MN)?
Short answer: The lawsuit is filed by Endo Pharmaceuticals Inc. against Perrigo UK FINCO Limited Partnership under a patent infringement framework associated with generic market entry for an Endo product. The matter is docketed in the US federal system under 1:19-cv-00437-MN.
What business teams usually look for in this case record
- Asserted patent list: publication/issuance numbers, assignees, and whether the claims are composition, method-of-use, or formulation.
- ANDA linkage: which application number (and whether it is a Paragraph IV notice case).
- Relief requested: permanent injunction scope, damages period, and specific infringement theories.
- Case posture: motion to dismiss, claim construction, summary judgment, trial, or settlement.
Because the asserted-patent and ANDA identifiers are not included in the provided input, a definitive “what patents protect what product” mapping cannot be stated in a way that would meet a litigation-grade standard.
Which patents are asserted in Endo v. Perrigo UK FINCO Limited Partnership (1:19-cv-00437-MN)?
Short answer: The asserted patent numbers, claim categories, and patent assignees are not provided in the prompt and cannot be reconstructed reliably without the complaint or docket exhibits.
Practical impact of not having the asserted-patent list
- Injunction strength depends on whether Endo asserted active ingredient composition versus formulation/method-of-use patents.
- Generic design-around feasibility depends on claim type and whether claim charts are narrow (single crystal form, specific excipient ratios, specific dosing regimen).
- Risk to launch date depends on whether a settlement resulted in an agreed carve-out or delayed launch tied to a particular patent or expiration.
How strong is Endo’s patent position against Perrigo in this case?
Short answer: Strength cannot be quantified from the provided case identifier alone because litigation-grade strength assessment depends on:
- claim construction outcomes (and if the court adopted Endo’s interpretations),
- validity rulings (anticipation/obviousness),
- infringement rulings (literal versus equivalents),
- and whether the case resolved via dismissal, consent judgment, or settlement.
What typically drives strength in Endo-type Hatch-Waxman disputes
- Composition-of-matter patents: harder for generics to design around.
- Formulation patents: sometimes solvable via alternate excipients or process changes, depending on claim language.
- Method-of-use patents: often attacked by inducement/delayed labeling arguments and by narrowness of “use” claims.
Without the asserted patents and outcomes, any scoring would be speculative.
What does the docket timeline for 1:19-cv-00437-MN indicate about case progress?
Short answer: The case is filed in 2019 and is assigned docket 1:19-cv-00437-MN. Specific filing dates, scheduling order milestones, Markman date, and motions are not provided.
How to interpret timeline signals once docket details are available
- Early dismissal: often indicates pleading defects or non-infringement arguments prevailing early.
- Claim construction (Markman) and summary judgment: indicates the court treated claim scope and validity as material.
- Stipulated dismissals or consent judgments: commonly correlate with settlements that trade money for exclusivity or delay.
No such procedural dates are provided here, so timeline inference is not possible.
Were Paragraph IV certifications involved, and what is Perrigo’s generic entry risk?
Short answer: In this class of litigation, Paragraph IV certifications are common, but the prompt does not include the ANDA number, certification type, or notice details. The generic entry risk cannot be tied to a specific exclusivity trigger without:
- the patent list,
- the “certified” paragraph IV patents,
- and settlement timing.
Business framework for generic entry risk (what to check in the docket)
- Whether Endo sued on all listed Orange Book patents or only a subset.
- Whether the case resolved with:
- carve-out (generic launches before some patents expire),
- total delay (generic launch pushed to later expiration),
- or final win for Endo (full injunction risk).
- Whether there is an entry-stay or temporary restraining order.
Without those artifacts, a case-specific entry-risk statement would be ungrounded.
Did Endo and Perrigo reach a settlement in 1:19-cv-00437-MN, and what terms matter commercially?
Short answer: Settlement terms are not included in the prompt. A litigation-grade settlement analysis requires:
- whether the case was dismissed “with prejudice”,
- whether it was resolved by consent judgment,
- and any published agreement terms (launch date, design-around limitations, royalties, or mutual covenants).
Commercial settlement terms that move revenue
- Launch date tied to a particular patent expiration
- Label restrictions (indications, dosing, patient subgroup)
- Manufacturing limits (process, excipient selection, impurity specs)
- Ongoing royalties or milestone payments
- Dismissal scope (with respect to all asserted patents or only some)
No settlement facts are present in the provided input.
What is the FDA and Orange Book status relevant to this litigation?
Short answer: The FDA regulatory status, ANDA linkage, and Orange Book listings are not provided in the prompt. These are essential to map:
- whether the litigation concerns an ANDA “generic drug” pathway,
- whether single-entity or combination product patents are at issue,
- and which exclusivity periods (including non-patent exclusivities) could extend time-to-entry.
How does this Endo v. Perrigo case compare with other Endo vs. generic litigations?
Short answer: A comparative analysis requires:
- asserted-patent patterns from Endo’s other cases,
- resolution patterns (in many cases: settlement versus final judgment),
- and product category.
No other case identifiers are provided, and the asserted-patent list for this case is missing, so a defensible comparison cannot be produced.
Key case artifacts business teams should extract from the docket (checklist)
This section is a docket-extraction blueprint for counsel and business development teams reviewing 1:19-cv-00437-MN:
- Complaint: product identity, ANDA number (if referenced), asserted patents (numbers and dates), counts for infringement, and requested remedies.
- Paragraph IV notice reference (if included): certified patents and the specific invalidity/non-infringement grounds.
- Answer and responsive motions: defenses (non-infringement, invalidity, unenforceability, lack of jurisdiction).
- Markman / claim construction order: construal of key claim terms.
- Summary judgment orders: validity and infringement determinations.
- Stipulations and dismissals: settlement progress indicators.
- Final judgment / consent judgment: explicit injunction/delay terms and which patents remain in the case.
- Settlement exhibits (if public): launch timing, design-around constraints, and damages/royalty structures.
Key Takeaways
- The case Endo Pharmaceuticals Inc. v. Perrigo UK FINCO Limited Partnership is docketed as 1:19-cv-00437-MN and is a patent infringement dispute connected to generic entry planning.
- A litigation-grade summary of asserted patents, claim scope, invalidity/infringement theories, procedural posture, and resolution/settlement terms cannot be completed from the prompt’s limited identifiers.
- For high-stakes decisions (licensing, launch planning, litigation strategy), the next step is to pull the docket’s complaint and orders to identify: (i) asserted patents, (ii) ANDA linkage, (iii) court rulings, and (iv) whether a settlement set a launch date or carve-out.
FAQs
- What court and judge handle Endo v. Perrigo UK FINCO Limited Partnership (1:19-cv-00437-MN)?
- Which Orange Book patents listed against the implicated Endo drug are typically challenged in cases like 1:19-cv-00437-MN?
- What does a dismissal “with prejudice” versus “without prejudice” usually imply for generic launch risk?
- How do method-of-use versus composition patents change design-around feasibility in Hatch-Waxman disputes?
- How do settlement launch dates in ANDA litigation translate into FDA labeling and manufacturing constraints post-entry?
References
- Federal case docket: Endo Pharmaceuticals Inc. v. Perrigo UK FINCO Limited Partnership, 1:19-cv-00437-MN.
